Lexicon Pharmaceuticals
LXRX
126 hedge funds and large institutions have $940M invested in Lexicon Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 15 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.64% less ownership
Funds ownership: 105.58% → 103.95% (-1.6%)
5% less funds holding
Funds holding: 133 → 126 (-7)
15% less capital invested
Capital invested by funds: $1.1B → $940M (-$162M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
66% less call options, than puts
Call options by funds: $450K | Put options by funds: $1.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$6.81M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.08M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$1.32M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$1.28M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$984K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$9.65M |
| 2 |
UIM
USS Investment Management
London,
United Kingdom
|
-$7.08M |
| 3 |
Millennium Management
New York
|
-$3.77M |
| 4 |
Renaissance Technologies
New York
|
-$2.55M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.36M |
LXRX Hedge Fund Activity: Q1 2018 in Review
126 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2018, worth a combined $940M — down 15% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LXRX and 9 opened new positions — a net loss of 6 holders — while 37 trimmed existing stakes and 41 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $6.81M. The largest seller was VOYA Investment Management, cutting an estimated $9.65M.
- 126 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2018, down from 133 in Q4 2017.
- Funds reported $940M of Lexicon Pharmaceuticals stock for Q1 2018, down 15% quarter-over-quarter.
- 9 funds opened new Lexicon Pharmaceuticals positions in Q1 2018 and 15 closed out, a net change of -6 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2018 was Marshall Wace, an estimated $6.81M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2018 was VOYA Investment Management, an estimated $9.65M sold.
Based on aggregated 13F filings for Q1 2018.